While good glycemic control has been shown to prevent microvascular complications (e.g. retinopathy, nephropathy, neuropathy), only a few anti-diabetic agents have been shown to reduce macrovascular complications (e.g. cardiovascular events. Empagliflozin, a sodium glucose transporter-2 (SGLT2) inhibitor, not only reduced the risk of CV events but also all-cause mortality in the EMPA-REG OUTCOME study. Based on this data, the SGLT2 inhibitors were given favorable second-line treatment status in the most recent AACE/ACE clinical practice guidelines. But do all SGLT2 inhibitors confer the same benefits… and risks? The Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS) trial assessed the cardiovascular and renal benefits from long-term canagliflozin use. The results are both reassuring and unexpected.
Guest Author: Sean Lasota, Pharm.D.
Music by Good Talk
Maybe Old is Gold? Newer Insulins Might Not Be Better – Just More Expensive
Using Controllers PRN for Mild Persistent Asthma – An Oxymoron?
The ZOE Trials – The Herpes Zoster Recombinant Subunit Vaccine — It’s Time to Upgrade!
Are You REAL-ly Paying Attention? The Importance of Attention Controls
Is it Time to “Step Up” Rescue Treatment for Asthma to Prevent Exacerbations?
Stop the Shots: Edoxaban vs Dalteparin in Cancer-Associated VTE Treatment
Hypertension – Time for Patients to Control the Wheel
Cutting Down HIV Treatment to a 2-Drug Regimen
Strategies for Managing Hypertension: Is the Paradigm Shifting?
Don’t Kid Yourself: Broad- versus Narrow-Spectrum Antibiotics in Children
Using Sotagliflozin In Tandem with Insulin: Weighing the Benefits in Type 1 Diabetes
Treating Opioid Use Disorder - X:BOT Offers a Pragmatic Approach
Can We KEEP Perimenopausal Women Sexually Satisfied?
Know When to Hold 'Em - Know When to Fold 'Em. Deprescribing in BPH.
ARCH Study: Is Romosozumab better than Alendronate for the Fracture-Prone?
SPRINTing towards lower BP goals : A re-analysis of the ACCORD-BP trial
Therapy for Early-Stage COPD: What is the GOLDen Regimen?
Inflammatory Statements about Cardiovascular Risk Reduction: The CANTOS Trial
Top Ten Things Every Clinician Should Know About the 2017 Hypertension Guidelines
Where is the COMPASS Taking Us? Rivaroxaban, Aspirin, or Both for Stable CVD ?
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive